Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Enterprise ValueMarket Capitalization

Immuneering (IMRX) Return on Equity: 2021-2023

Historic Return on Equity for Immuneering (IMRX) over the last 2 years, with Dec 2023 value amounting to -0.56%.

  • Immuneering's Return on Equity fell 13.00% to -0.56% in Q4 2023 from the same period last year, while for Dec 2023 it was -0.56%, marking a year-over-year decrease of 13.00%. This contributed to the annual value of -0.55% for FY2023, which is 17.00% down from last year.
  • Immuneering's Return on Equity amounted to -0.56% in Q4 2023, which was down 17.04% from -0.48% recorded in Q3 2023.
  • In the past 5 years, Immuneering's Return on Equity ranged from a high of -0.21% in Q4 2021 and a low of -0.56% during Q4 2023.
  • In the last 3 years, Immuneering's Return on Equity had a median value of -0.45% in 2022 and averaged -0.41%.
  • Its Return on Equity has fluctuated over the past 5 years, first climbed by 9bps in 2022, then declined by 23bps in 2023.
  • Over the past 3 years, Immuneering's Return on Equity (Quarterly) stood at -0.21% in 2021, then fell by 22bps to -0.44% in 2022, then decreased by 13bps to -0.56% in 2023.
  • Its last three reported values are -0.56% in Q4 2023, -0.48% for Q3 2023, and -0.49% during Q2 2023.